blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1545595

EP1545595 - MODIFIED TRANSFERRIN FUSION PROTEINS COMPRISING DUPLICATE TRANSFERRIN AMINO OR CARBOXY TERMINAL DOMAINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.05.2011
Database last updated on 31.08.2024
Most recent event   Tooltip19.10.2012Lapse of the patent in a contracting state
New state(s): TR		published on 21.11.2012  [2012/47]
Applicant(s)For all designated states
Biorexis Pharmaceutical Corporation
235 East 42nd Street
New York, NY 10017-5755 / US
[2008/26]
Former [2007/51]For all designated states
Biorexis Pharmaceutical Corporation
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
Former [2007/07]For all designated states
BioRexis Technology, Inc.
103 Foulk Road, Suite 202
Wilmington, DE 19803 / US
Former [2005/26]For all designated states
Biorexis Pharmaceutical Corporation
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
Inventor(s)01 / TURNER, Andrew, J.
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
02 / SADEGHI, Homayoun
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
 [2006/15]
Former [2005/26]01 / TURNER, Andrew J.
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
02 / SADEGHI, Homayoun
3400 Horizon Drive
King of Prussia, PA 19406-2675 / US
Representative(s)Porter, Jonathan Philip, et al
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2010/39]Porter, Jonathan Philip, et al
Pfizer Limited European Patent Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Former [2005/26]Cripps, Joanna Elizabeth, et al
Mewburn Ellis LLP York House 23 Kingsway
London WC2B 6HP / GB
Application number, filing date03791808.328.08.2003
[2005/26]
WO2003US26742
Priority number, dateUS20020406977P30.08.2002         Original published format: US 406977 P
[2005/26]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004020454
Date:11.03.2004
Language:EN
[2004/11]
Type: A2 Application without search report 
No.:EP1545595
Date:29.06.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 11.03.2004 takes the place of the publication of the European patent application.
[2005/26]
Type: B1 Patent specification 
No.:EP1545595
Date:07.07.2010
Language:EN
[2010/27]
Search report(s)International search report - published on:US04.11.2004
(Supplementary) European search report - dispatched on:EP18.04.2006
ClassificationIPC:A61K39/00, C07K14/79, A61K47/48, C12N15/62
[2009/40]
CPC:
A61K38/40 (EP,US); A61K47/644 (EP,US); A61P15/00 (EP);
A61P15/08 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P3/08 (EP); A61P3/10 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP);
A61P31/14 (EP); A61P31/18 (EP); A61P31/20 (EP);
A61P33/00 (EP); A61P35/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P7/06 (EP);
C07K14/005 (EP,US); C07K14/47 (EP,US); C07K14/565 (EP,US);
C07K14/70582 (EP,US); C07K14/79 (EP,US); C07K7/06 (EP,US);
C07K7/08 (EP,US); A01K2217/05 (EP,US); C07K2319/00 (EP,US);
C07K2319/035 (EP,US); C07K2319/31 (EP,US); C07K2319/40 (EP,US);
C12N2740/16122 (EP,US) (-)
Former IPC [2006/22]A61K39/00, C07K14/79, A61K47/48
Former IPC [2005/26]A61K39/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/26]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:MODIFIZIERTE TRANSFERRIN-FUSIONSPROTEINE MIT DOPPELTEN TRANSFERRIN-AMINO- ODER CARBOXY-TERMINALEN DOMÄNEN[2005/26]
English:MODIFIED TRANSFERRIN FUSION PROTEINS COMPRISING DUPLICATE TRANSFERRIN AMINO OR CARBOXY TERMINAL DOMAINS[2005/26]
French:PROTEINES DE FUSION MODIFIEES A TRANSFERRINE COMPRENANT DES DOMAINES AMINOTRANSFERRINE OU CARBOXY TERMINAL DUPLIQUES[2005/26]
Entry into regional phase21.03.2005National basic fee paid 
21.03.2005Search fee paid 
21.03.2005Designation fee(s) paid 
21.03.2005Examination fee paid 
Examination procedure21.03.2005Examination requested  [2005/26]
12.05.2005Amendment by applicant (claims and/or description)
08.10.2007Despatch of a communication from the examining division (Time limit: M06)
11.06.2008Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
21.08.2008Reply to a communication from the examining division
17.08.2009Cancellation of oral proceeding that was planned for 17.09.2009
17.09.2009Date of oral proceedings
17.09.2009Date of oral proceedings (cancelled)
13.01.2010Communication of intention to grant the patent
20.05.2010Fee for grant paid
20.05.2010Fee for publishing/printing paid
Opposition(s)08.04.2011No opposition filed within time limit [2011/24]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
18.08.2008Request for further processing filed
Fees paidRenewal fee
24.08.2005Renewal fee patent year 03
14.08.2006Renewal fee patent year 04
22.08.2007Renewal fee patent year 05
21.08.2008Renewal fee patent year 06
20.08.2009Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT07.07.2010
BE07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
TR07.07.2010
LU28.08.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
HU08.01.2011
[2012/47]
Former [2012/44]AT07.07.2010
BE07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
LU28.08.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
HU08.01.2011
Former [2012/42]AT07.07.2010
BE07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
HU08.01.2011
Former [2011/31]AT07.07.2010
BE07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
RO07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/23]AT07.07.2010
BE07.07.2010
CY07.07.2010
CZ07.07.2010
DK07.07.2010
EE07.07.2010
FI07.07.2010
NL07.07.2010
SE07.07.2010
SI07.07.2010
SK07.07.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/20]AT07.07.2010
BE07.07.2010
CY07.07.2010
DK07.07.2010
FI07.07.2010
NL07.07.2010
SE07.07.2010
SI07.07.2010
CH31.08.2010
LI31.08.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/19]AT07.07.2010
BE07.07.2010
CY07.07.2010
DK07.07.2010
FI07.07.2010
NL07.07.2010
SE07.07.2010
SI07.07.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/16]AT07.07.2010
BE07.07.2010
CY07.07.2010
FI07.07.2010
NL07.07.2010
SE07.07.2010
SI07.07.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/15]AT07.07.2010
CY07.07.2010
FI07.07.2010
NL07.07.2010
SE07.07.2010
SI07.07.2010
MC31.08.2010
BG07.10.2010
GR08.10.2010
PT08.11.2010
Former [2011/13]AT07.07.2010
CY07.07.2010
FI07.07.2010
NL07.07.2010
SI07.07.2010
BG07.10.2010
PT08.11.2010
Former [2011/12]AT07.07.2010
FI07.07.2010
NL07.07.2010
SI07.07.2010
BG07.10.2010
PT08.11.2010
Former [2011/10]AT07.07.2010
FI07.07.2010
NL07.07.2010
SI07.07.2010
PT08.11.2010
Former [2011/08]AT07.07.2010
NL07.07.2010
SI07.07.2010
Former [2010/52]SI07.07.2010
Documents cited:Search[A]WO9502421  (ALKERMES INC [US], et al) [A] 1-37 * abstract *;
 [A]US5986067  (FUNK WALTER D [US], et al) [A] 1-37 * abstract * * column 3, line 44 - column 4, line 64 * * column 14, line 39 - column 17, line 44 *;
 [A]  - PARK E ET AL, "Production and characterization of fusion proteins containing transferrin and nerve growth factor", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, (1998), vol. 6, no. 1, ISSN 1061-186X, pages 53 - 64, XP002960815 [A] 1-37 * abstract * * page 60, column 2, paragraph 3 - page 61, column 1, paragraph 1; figure 1 *
 [A]  - MACGILLIVRAY ET AL, "The primary structure of human serum transferin", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (19830325), vol. 258, no. 6, pages 3543 - 3553, XP002985528 [A] 1-37 * abstract *
 [A]  - ALI S A ET AL, "TRANSFERRIN TROJAN HORSES AS A RATIONAL APPROACH FOR THE BIOLOGICAL DELIVERY OF THERAPEUTIC PEPTIDE DOMAINS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (19990820), vol. 274, no. 34, ISSN 0021-9258, pages 24066 - 24073, XP008052346 [A] 1-37 * abstract * * page 24071, column 2 * * page 24072, column 1, paragraph 5 - column 2 *

DOI:   http://dx.doi.org/10.1074/jbc.274.34.24066
 [A]  - WAGNER E ET AL, "DELIVERY OF DRUGS, PROTEINS AND GENES INTO CELLS USING TRANSFERRIN AS A LIGAND FOR RECEPTOR-MEDIATED ENDOCYTOSIS", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, (199401), vol. 14, ISSN 0169-409X, pages 113 - 135, XP000472988

DOI:   http://dx.doi.org/10.1016/0169-409X(94)90008-6
International search[Y]  - JACOBS E. ET AL, "Human transferrin precursor", GENBANK, (19941125), Database accession no. (AAR66492), XP002903253
by applicantWO9008832
 WO9423744
 US5986067
    - MA ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1997), vol. 94, pages 12744 - 12746
    - CRANAGE, EMBO J., (1986), vol. 5, pages 3057 - 3063
    - MCKNIGHT ET AL., EMBO J., (1985), vol. 4, pages 2093 - 2099
    - WALL ET AL., J. CELL. BIOCHEM., (1992), vol. 49, page 113
    - JANENICH, PROC. NATL. ACAD. SCI. USA, (1976), vol. 73, page 1260
    - JANENICH ET AL., CELL, (1981), vol. 24, page 519
    - STUHLMANN ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, page 7151
    - JAHNER ET AL., PROC. NATL. ACAD SCI. USA, (1985), vol. 82, page 6927
    - VAN DER PUTTEN ET AL., PROC. NATL. ACAD SCI. USA, (1985), vol. 82, pages 6148 - 6152
    - STEWART, EMBO J., (1987), vol. 6, pages 383 - 388
    - JAHNER, D. ET AL., NATURE, (1982), vol. 298, page 623
    - HASKELL; BOWEN, MOL. REPROD. DEV., (1995), vol. 40, page 386
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.